$115MSeries D, 17 November 2025
Funds expansion of clinical trials for alnodesertib and a Phase 2 study of ART6043.
- Amount
- $115M
- Stage
- Series D
- Announced
- 17 November 2025
- Lead
- SV Health Investors
- Other investors
- RA Capital Management, Janus Henderson Investors, Pfizer Ventures, Novartis Venture Fund
- Use of funds
- Funds expansion of clinical trials for alnodesertib and a Phase 2 study of ART6043.
- Checked
- Announced by the company
- Sources
- Artios announces oversubscribed $115M Series D sofinnovapartners.com
Artios announces oversubscribed $115M Series D cooley.com